Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,077
Employees1,077
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,077
Employees1,077

EXEL Key Statistics

Market cap
12.55B
Market cap12.55B
Price-Earnings ratio
16.54
Price-Earnings ratio16.54
Dividend yield
Dividend yield
Average volume
2.79M
Average volume2.79M
High today
High today
Low today
Low today
Open price
$48.89
Open price$48.89
Volume
0.00
Volume0.00
52 Week high
$51.63
52 Week high$51.63
52 Week low
$33.76
52 Week low$33.76

Stock Snapshot

As of today, Exelixis(EXEL) shares are valued at $49.68. The company's market cap stands at 12.55B, with a P/E ratio of 16.54.

On 2026-05-21, Exelixis(EXEL) stock opened at $48.89, reached a high of —, and a low of —.

The Exelixis(EXEL)'s current trading volume is 0, compared to an average daily volume of 2.79M.

In the last year, Exelixis(EXEL) shares hit a 52-week high of $51.63 and a 52-week low of $33.76.

In the last year, Exelixis(EXEL) shares hit a 52-week high of $51.63 and a 52-week low of $33.76.

EXEL News

Zacks 17h
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study - Zacks Investment Research

...

EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study - Zacks Investment Research
TipRanks 1d
Top Exelixis Executive Cashes In on Major Stock Sale

New insider activity at Exelixis ( (EXEL) ) has taken place on May 19, 2026. Unlock hedge fund-level data and powerful investing tools for smarter, sharper dec...

TipRanks 1d
Exelixis Earnings Call Highlights Strong Cabo Momentum

Exelixis ((EXEL)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and powerful i...

Analyst ratings

48%

of 21 ratings
Buy
47.6%
Hold
47.6%
Sell
4.8%

More EXEL News

TipRanks 2d
Exelixis announces clinical development collaboration with Merck

Exelixis (EXEL) announced that the company has entered into a clinical development collaboration with Merck (MRK), known as MSD outside of the United States and...

TipRanks 3d
Exelixis Advances Zanzalintinib Into Phase 2 Meningioma Trial, Signaling Pipeline Expansion

Exelixis (EXEL) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

Simply Wall St 3d
A Look At Exelixis Valuation After Strong Q1 2026 Results And Confirmed 2026 Guidance

Exelixis (EXEL) stock is in focus after the company reported first quarter 2026 results, maintained full year revenue guidance of US$2.525b to US$2.625b, and hi...

A Look At Exelixis Valuation After Strong Q1 2026 Results And Confirmed 2026 Guidance
Nasdaq 5d
Prediction: This Stock Could Double By 2031

Key Points Exelixis's main product should continue driving growth through the end of the decade. The company is close to earning approval for a medicine that...

Prediction: This Stock Could Double By 2031

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.